Close Menu

NEW YORK – Researchers at the Fred Hutchinson Cancer Research Center have established a CLIA laboratory focused on running targeted proteomic assays by multiple reaction monitoring mass spectrometry, making it one of the few labs anywhere set up specifically to use the method for clinical purposes.

Led by Fred Hutch professor Amanda Paulovich, the lab plans to launch an MRM mass spec assay for HER2 as its first CLIA-certified offering with a test for the immuno-oncology marker PD-L1 likely to follow.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.